What is CG Oncology, Inc. Common stock's Market Cap?

CG Oncology, Inc. Common stock's Market Cap is $6.5B, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's Enterprise Value?

CG Oncology, Inc. Common stock's Enterprise Value is $5.4B, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's Price / Sales?

CG Oncology, Inc. Common stock's Price / Sales is 1037.7×, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's EV / Revenue?

CG Oncology, Inc. Common stock's EV / Revenue is 873.1×, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's EV / EBITDA?

CG Oncology, Inc. Common stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's Revenue (TTM)?

CG Oncology, Inc. Common stock's Revenue (TTM) is $6.2M, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's Net Income (TTM)?

CG Oncology, Inc. Common stock's Net Income (TTM) is -$224.4M, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's EBITDA?

CG Oncology, Inc. Common stock's EBITDA is -$249.7M, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's Diluted EPS (TTM)?

CG Oncology, Inc. Common stock's Diluted EPS (TTM) is -2.53, based on as-reported figures from SEC (XBRL) filings.

What is CG Oncology, Inc. Common stock's EBITDA Margin?

CG Oncology, Inc. Common stock's EBITDA Margin is -4008.7%, based on as-reported figures from SEC (XBRL) filings.

CG Oncology, Inc. Common stock (CGON) Financial Statements

CG Oncology, Inc. Common stock

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG00YHKK4R2

XNAS · usd

72.91▼ 0.49 (-0.67%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close73.40

Day's Range72.25 – 74.60

52-Week Range32.08 – 80.97

Volume550.2K

Avg Volume713.1K

Share Statistics

Shares Outstanding

Employees142

ExchangeXNAS

Listed2024-01-25

Share count as of August 5, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about CG Oncology, Inc. Common stock (CGON)

What is CG Oncology, Inc. Common stock's Market Cap?: CG Oncology, Inc. Common stock's Market Cap is $6.5B, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's Enterprise Value?: CG Oncology, Inc. Common stock's Enterprise Value is $5.4B, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's Price / Sales?: CG Oncology, Inc. Common stock's Price / Sales is 1037.7×, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's EV / Revenue?: CG Oncology, Inc. Common stock's EV / Revenue is 873.1×, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's EV / EBITDA?: CG Oncology, Inc. Common stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's Revenue (TTM)?: CG Oncology, Inc. Common stock's Revenue (TTM) is $6.2M, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's Net Income (TTM)?: CG Oncology, Inc. Common stock's Net Income (TTM) is -$224.4M, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's EBITDA?: CG Oncology, Inc. Common stock's EBITDA is -$249.7M, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's Diluted EPS (TTM)?: CG Oncology, Inc. Common stock's Diluted EPS (TTM) is -2.53, based on as-reported figures from SEC (XBRL) filings.
What is CG Oncology, Inc. Common stock's EBITDA Margin?: CG Oncology, Inc. Common stock's EBITDA Margin is -4008.7%, based on as-reported figures from SEC (XBRL) filings.